EU reimbursement: country variations in value assessment and the key routes to market entry
This article was originally published in Clinica
Reimbursement of medical technology is linked to the value offered by the product. Some of this value is intrinsic to the technology and is constant across all EU markets; some varies by market according to the country's specific reimbursement rules, coding, current standard of care, professional practice, and differing unit costs. Dr Mark Charny of UK consultancy Translucency looks at which elements of value can apply across the EU, which are country-specific and how best to use value to access these markets
You may also be interested in...
In the final part of Clinica’s series on heath technology assessment in the EU, Mark Charny looks beyond HTA and discusses what factors to consider when gauging the reimbursement potential of your product from a payer’s perspective
In the second part of Clinica’s new series on health technology assessment in the EU, Mark Charny discusses how medtech companies can plan their HTA strategy on a country-specific level and on a broader EU level
Mark Charny provides an update on the key initiatives that have been rolled out in the EU to support cross-border collaboration on health technology assessment for medical devices.